TY - JOUR
T1 - Transforming growth factor-β1 stimulates heme oxygenase-1 expression via the PI3K/Akt and NF-κB pathways in human lung epithelial cells
AU - Lin, Chen Chun
AU - Chiang, Ling Ling
AU - Lin, Chien Huang
AU - Shih, Chung Hung
AU - Liao, Yi Ting
AU - Hsu, Ming Jen
AU - Chen, Bing Chang
N1 - Funding Information:
This study was sponsored by the Shin Kong Wu Ho-Su Memorial Hospital (SKH-TMU-92-02).
PY - 2007/4/10
Y1 - 2007/4/10
N2 - A previous report showed that transforming growth factor-β1 (TGF-β1) can induce heme oxygenase-1 (HO-1) expression, attenuate cellular injury, and maintain tissue homeostasis. In this study, we investigated the involvement of phosphoinositide-3-OH-kinase (PI3K)/Akt and the nuclear factor-κB (NF-κB) signaling pathway in TGF-β1-induced HO-1 expression in human lung epithelial cells (A549). Treatment of A549 cells with TGF-β1 caused HO-1 to be expressed in a concentration- and time-dependent manner. Treatment of A549 cells with LY 294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, a PI3K inhibitor), an Akt inhibitor, and the dominant negative mutant of Akt (Akt DN) inhibited TGF-β1-induced HO-1 expression and HO-1-luciferase activity. Stimulation of cells with TGF-β1 caused an increase in Akt phosphorylation in a time-dependent manner, which was inhibited by wortmannin and LY 294002 (PI3K inhibitors). In addition, treatment of A549 cells with Bay 117082 ((E)-3-[4-methylphenylsulfonyl]-2-propenenitrile, an IκB phosphorylation inhibitor), pyrrolidine dithiocarbamate (PDTC, an NF-κB inhibitor), and the dominant negative mutant of IκBα (IκBαM) inhibited TGF-β1-induced HO-1 expression and HO-1-luciferase activity. Treatment of A549 cells with TGF-β1-induced IκB kinase α/β (IKKα/β) phosphorylation, IκBα phosphorylation, IκBα degradation, p65 Ser536 phosphorylation, and κB-luciferase activity. The TGF-β1-mediated increases in IKKα/β phosphorylation, p65 Ser536 phosphorylation, and κB-luciferase activity were inhibited by LY 294002, an Akt inhibitor, and Akt DN. Taken together, these results suggest that the PI3K/Akt dependent IKKα/β/NF-κB signaling pathway plays an important role in TGF-β1-induced HO-1 expression in A549 cells.
AB - A previous report showed that transforming growth factor-β1 (TGF-β1) can induce heme oxygenase-1 (HO-1) expression, attenuate cellular injury, and maintain tissue homeostasis. In this study, we investigated the involvement of phosphoinositide-3-OH-kinase (PI3K)/Akt and the nuclear factor-κB (NF-κB) signaling pathway in TGF-β1-induced HO-1 expression in human lung epithelial cells (A549). Treatment of A549 cells with TGF-β1 caused HO-1 to be expressed in a concentration- and time-dependent manner. Treatment of A549 cells with LY 294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, a PI3K inhibitor), an Akt inhibitor, and the dominant negative mutant of Akt (Akt DN) inhibited TGF-β1-induced HO-1 expression and HO-1-luciferase activity. Stimulation of cells with TGF-β1 caused an increase in Akt phosphorylation in a time-dependent manner, which was inhibited by wortmannin and LY 294002 (PI3K inhibitors). In addition, treatment of A549 cells with Bay 117082 ((E)-3-[4-methylphenylsulfonyl]-2-propenenitrile, an IκB phosphorylation inhibitor), pyrrolidine dithiocarbamate (PDTC, an NF-κB inhibitor), and the dominant negative mutant of IκBα (IκBαM) inhibited TGF-β1-induced HO-1 expression and HO-1-luciferase activity. Treatment of A549 cells with TGF-β1-induced IκB kinase α/β (IKKα/β) phosphorylation, IκBα phosphorylation, IκBα degradation, p65 Ser536 phosphorylation, and κB-luciferase activity. The TGF-β1-mediated increases in IKKα/β phosphorylation, p65 Ser536 phosphorylation, and κB-luciferase activity were inhibited by LY 294002, an Akt inhibitor, and Akt DN. Taken together, these results suggest that the PI3K/Akt dependent IKKα/β/NF-κB signaling pathway plays an important role in TGF-β1-induced HO-1 expression in A549 cells.
KW - Akt
KW - HO-1 [Heme oxygenase-1]
KW - Human lung epithelial cell
KW - NF-κB [Nuclear factor-κB]
KW - PI3K [Phosphoinositide-3-OH-kinase]
KW - TGF-β1 [Transforming growth factor-β1]
UR - http://www.scopus.com/inward/record.url?scp=33847381862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847381862&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2007.01.025
DO - 10.1016/j.ejphar.2007.01.025
M3 - Article
C2 - 17307160
AN - SCOPUS:33847381862
SN - 0014-2999
VL - 560
SP - 101
EP - 109
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -